Ruxolitinib (Jakavi) for the indication symptomatic treatment of myelofibrosis

Ruxolitinib has an added value in comparison with placebo or BAT in the treatment of the disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post-essentialthrombocythaemia myelofibrosis.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.